BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naive ALK-rearranged advanced NSCLC.

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPELAMIN, YasirGANDHI, SaumilANTONOFF, MaraMOTT, FrankGIBBONS, Don LynnLE, XiuningNEGRAO, Marcelo VailatiSEPESI, BorisKARAM, Jose A.CASCONE, TinaWANG, LinghuaBLUMENSCHEIN, GeorgeGLISSON, Bonnie S.TSAO, Anne S.HEYMACH, John2021-01-252021-01-252020JOURNAL OF CLINICAL ONCOLOGY, v.38, n.15, suppl.S, 20200732-183Xhttps://observatorio.fm.usp.br/handle/OPI/38976engrestrictedAccessBRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naive ALK-rearranged advanced NSCLC.conferenceObjectCopyright AMER SOC CLINICAL ONCOLOGYOncology1527-7755